Abstract
Children with growth hormone deficiency are currently treated with daily injections of recombinant growth hormone. The burden due to 365 injections per year and cold chain storage causes a poor medication adherence. Long-acting GH was developed to decrease injection frequency and to therefore promote a better therapeutic compliance. In this paper, we discuss about which long-acting drugs are currently on the market, their mechanism of action and which groups of patients may benefit from them.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
